Vanda Pharmaceuticals Inc.
VNDABiotechnology
$4.05+1.25%As of Oct 29vs prior close
- Market cap
- $244.9M
- P/E (TTM)
- –
- P/E (FY1)
- 4.2×
- From 52W high
- −57.64%
- EPS (LTM)
- -$4.63
- Revenue (LTM)
- $229.3M
- Net margin
- -119.87%
- Dividend yield
- 0.00%
Nomior Score
45
Steady ProfileSpeculativeBottom 39% of the scored universe
Growth53
Quality31
Value61
Momentum51
Resilience44
Growth
+4.45%revenue a year over 9 fiscal years
FY16 $146MLTM $229.3M
Connections
Revenue to profitQ3 FY26
The operating loss was 34% of revenue, narrower by 22 pts on a year.
Latest resultsthird quarter 2026
- Net loss
- $22.6 million
Product sales rose in the third quarter, led by Fanapt and an early contribution from the NEREUS launch, and HETLIOZ sales also increased after orders shipped at the end of the prior quarter were recognized in this period. Operating expenses fell from the prior quarter as Phase III and launch preparation activities concluded, but the company still reported a net loss. Management expects further expense reductions and updated its full-year revenue outlook.
Who owns it
2funds